首页> 外文期刊>Journal of Microencapsulation: Microcapsules Liposomes Nanoparticles Microcells Microspheres >Dissolution stability studies of suspensions of prolonged-release diclofenac microcapsules prepared by the Wurster process:I.Eudragit-based formulation and possible drug-excipient interaction
【24h】

Dissolution stability studies of suspensions of prolonged-release diclofenac microcapsules prepared by the Wurster process:I.Eudragit-based formulation and possible drug-excipient interaction

机译:Wurster法制备的双氯芬酸缓释微胶囊悬液的溶出度稳定性研究:I。基于Eudragit的制剂和可能的药物-赋形剂相互作用

获取原文
获取原文并翻译 | 示例
           

摘要

The aim was to evaluate possible interaction in solid and liquid state of the drug with formulation excipients consequent to very fast drug release of diclofenac-Eudragit~R prolonged release micro-capsules.The microcapsules were prepared by drug layering on calcium carbonate cores and coated with Eudragit~R RS 30D and L30D-55 as previously reported.Suspension of the microcapsules was prepared using microcrystalline cellulose/sodium carboxymethyl cellulose(Avicel~R CL-611)as medium.In vitro dissolution testing of the suspension was done,and,based on the dissolution results,possible interaction between diclofenac and Eudragit and Avicel in the medium was studied.Powder X-ray dififraction(PXRD)and differential scanning calorimetry(DSC)analyses were performed using 1:1 binary,1:1:1 ternary mixtures and a ratio equivalent to that in the formulation.The mixtures were prepared by mixing the dispersions-Eudragit RS 30D or L30D-55 with the drug or other components,followed by drying at 60 deg C for 48 h.Dry mixing was done using the powder equivalents of the polymers,Eudragit RS PO and L100-55,Avicel and calcium carbonate.In vitro dissolution of the suspended microcapsules showed a very fast release after 48 h(T_(50)=<1h)compared to the solid microcapsules(T_(50)=6h).DSC curves of the formulation components or microcapsules did not show the characteristic endothermic peak of diclofenac at 287 deg C.Powder X-ray diffraction of the binary or ternary mixtures of diclofenac and Eudragit polymers indicated reduction,shift or modification of the crystalline peaks of the drug or excipients at 29 of 12 deg and 18 deg ,suggestive of interaction.Some changes in drug peak characteristics at 18 deg and 23 deg were observed for Avicel/ drug mixture,though not significant.The DSC curves of the binary mixture of diclofenac co-dried with liquid forms of Eudragit(i.e.RS 30D or L30D-55)revealed greater interaction compared to the curves of drug and powdered forms of Eudragit(RS PO or L100-55).This was depicted by greater shift in fusion points of the mixtures relative to the drug.However,comparing the RS and L-type Eudragit,the latter generally showed greater interaction with the drug.Interaction between diclofenac and L-type Eudragit polymers can occur in liquid formulations.
机译:目的是评估双氯芬酸-Eudragit〜R缓释微胶囊的快速药物释放后,药物与赋形剂在固体和液体状态下可能的相互作用。如先前报道的Eudragit〜R RS 30D和L30D-55。以微晶纤维素/羧甲基纤维素钠(Avicel〜R CL-611)为介质制备微胶囊的悬浮液。根据溶出度的结果,研究了双氯芬酸与Eudragit和Avicel在介质中可能的相互作用。使用1:1二元,1:1:1三元混合物进行粉末X射线衍射(PXRD)和差示扫描量热(DSC)分析通过将分散体-Eudragit RS 30D或L30D-55与药物或其他成分混合,然后在60摄氏度下干燥,来制备混合物搅拌48小时后,用Eudragit RS PO和L100-55,Avicel和碳酸钙等聚合物的粉末当量干混。悬浮的微胶囊在体外溶解48小时后显示出非常快的释放(T_(50)=与固体微胶囊(T_(50)= 6h)相比<1h)。制剂成分或微胶囊的DSC曲线未显示双氯芬酸在287摄氏度时的吸热峰。二元或三元混合物的粉末X射线衍射双氯芬酸和Eudragit聚合物的含量表明,药物或赋形剂在12度和18度29度处的结晶峰减少,移动或修饰,表明相互作用.Avicel /在18度和23度处观察到一些药物峰特征变化与药物和粉末形式的Eudragit(RS PO)共同干燥的双氯芬酸二元混合物与Eudragit液体形式(即RS 30D或L30D-55)的DSC曲线显示出更大的相互作用或L100-55)混合物的融合点相对于药物的变化更大来描述这一点。但是,与RS和L型Eudragit相比,后者通常显示出与药物更大的相互作用。双氯芬酸和L型Eudragit聚合物之间可能发生相互作用在液体制剂中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号